Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy

[11] Yu I-R(1992)Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill Br J Cancer. 65 27-32

[12] Holloway R(2007)Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable non-small-cell lung cancer Cancer. 109 1829-1835

[13] Mehta R(2004)Trastuzumab in the treatment of advanced non–small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598 J Clin Oncol 22 1180-1187

[14] Finkler N(2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group J Clin Oncol. 26 3552-3559

[15] Parker RJ(2007)Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol. 25 5240-5247

[16] Fruehauf JP(2009)KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc. 6 201-205

[17] Mehta R(2006)A genomic strategy to refine prognosis in early-stage non-small cell lung cancer N Engl J Med 355 570-580

[18] d’Amato TA(2007)A five-gene signature and clinical outcome in non-small-cell lung cancer N Engl J Med. 356 11-20

[19] Landreneau RJ(2009)Prognostic gene signatures for non-small-cell lung cancer Proc Natl Acad Sci. 106 2824-2828

[20] McKenna RJ(2007)Adjuvant chemotherapy and the role of chemoresistance testing for stage I non-small cell lung cancer Thorac Surg Clin. 17 287-299

[11] Yu I-R(1992)Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill Br J Cancer. 65 27-32

[12] Holloway R(2007)Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable non-small-cell lung cancer Cancer. 109 1829-1835

[13] Mehta R(2004)Trastuzumab in the treatment of advanced non–small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598 J Clin Oncol 22 1180-1187

[14] Finkler N(2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group J Clin Oncol. 26 3552-3559

[15] Parker RJ(2007)Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol. 25 5240-5247

[16] Fruehauf JP(2009)KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc. 6 201-205

[17] Mehta R(2006)A genomic strategy to refine prognosis in early-stage non-small cell lung cancer N Engl J Med 355 570-580

[18] d’Amato TA(2007)A five-gene signature and clinical outcome in non-small-cell lung cancer N Engl J Med. 356 11-20

[19] Landreneau RJ(2009)Prognostic gene signatures for non-small-cell lung cancer Proc Natl Acad Sci. 106 2824-2828

[20] McKenna RJ(2007)Adjuvant chemotherapy and the role of chemoresistance testing for stage I non-small cell lung cancer Thorac Surg Clin. 17 287-299